144 completed, 105 recruiting, 87 terminated, 59 active not recruiting. 462 Phase 1, 175 Phase 2.
Follow Triple Negative Breast Neoplasms: new trials by email Literature Review of Triple Negative Breast Neoplasms trials Research Report on Triple Negative Breast Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. BLEX 404 Oral Liquid - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | BioLite, Inc. | 44 | 2027-01-01 | 2026-04-13 |
| Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies CRG-150 - HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | CoRegen, Inc. | 67 | 2026-11-01 | 2026-10-02 |
| A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors. LNTH-2403 - Imaging, Colorectal Cancer | Phase 1 | Not yet recruiting | Radiopharm Theranostics, Ltd | 16 | 2026-10-30 | 2026-08-12 |
| Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer Biopsy Procedure, Biospecimen Collection, Echocardiography Test - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 36 | 2026-10-06 | 2026-10-16 |
| Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients Paclitaxel, Carboplatin, Pembrolizumab - Triple Negative Breast Cancer | Phase 1 | Not yet recruiting | Washington University School of Medicine | 30 | 2026-10-01 | 2026-09-04 |
| Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) Zn-Telomir - Triple-Negative Breast Cancer (TNBC), Advanced Triple-Negative Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Telomir Pharmaceuticals, Inc. | 76 | 2026-10-01 | 2026-06-23 |
| Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC Group 1-Isunakinra - Triple-Negative Breast Cancer (TNBC) | Phase 1 / Phase 2 | Not yet recruiting | University Health Network, Toronto | 60 | 2026-10-01 | 2026-10-22 |
| A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors. YF550 - Solid Tumor (Phase I), Ovarian Cancer | Phase 1 | Not yet recruiting | InventisBio Yiqi Beijing Limited | 204 | 2026-10-01 | 2026-10-26 |
| Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer Neoadjuvant Chemotherapy, Radiation Therapy, MRI - Breast Cancer, HER2-positive Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 84 | 2026-09-15 | 2026-06-24 |
| A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors [68Ga]Ga-DWJ155 - Advanced Gastroesophageal Adenocarcinoma, Advanced Breast Cancer | Phase 1 | Recruiting | Novartis Pharmaceuticals | 66 | 2026-09-08 | 2026-10-13 |
| A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers CT-202 - Triple Negative Breast Cancer (TNBC), Colorectal Cancer | Phase 1 | Recruiting | Context Therapeutics Inc. | 162 | 2026-09-01 | 2026-10-08 |
| A Study of IOV-5001 in Adults With Advanced Solid Tumors IOV-5001 - Advanced Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | Iovance Biotherapeutics, Inc. | 106 | 2026-09-01 | 2026-09-15 |
| Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy BreakVax, Ipilimumab 2.5 mg, Pembrolizumab - Triple-Negative Breast Cancer (TNBC) | Phase 1 / Phase 2 | Not yet recruiting | BreakBio Corp | 10 | 2026-09-01 | 2026-08-19 |
| GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours Fludarabine, Cyclophosphamide, GCAR1 - Alveolar Soft Part Sarcoma, Renal Cell Carcinoma | Phase 1 | Recruiting | Canadian Cancer Trials Group | 30 | 2026-08-30 | 2026-10-16 |
| Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease Tislelizumab + Bevacizumab + Capecitabine - Advanced Solid Tumor Cancer, Triple-Negative Breast Cancer (TNBC) | Phase 1 / Phase 2 | Not yet recruiting | National University Hospital, Singapore | 154 | 2026-08-01 | 2026-07-10 |
| Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study Epirubicin and cyclophosphamide followed by paclitaxel oral solution - Triple -Negative Breast Cancer | Phase 1 / Phase 2 | Recruiting | Liu Shu | 30 | 2026-07-30 | 2026-08-04 |
| Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype Dexamethasone, Bortezomib, LENALIDOMIDE - Multiple Myeloma, Triple Negative Breast Cancer | Phase 1 | Recruiting | Andrew Hantel, MD | 90 | 2026-07-30 | 2026-08-17 |
| A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors ARV-6723, Pembrolizumab, SOC - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Arvinas Inc. | 499 | 2026-07-29 | 2026-10-13 |
| Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer ITI-5000 mRNA Vaccine, Pembrolizumab, Olaparib - Triple Negative Breast Cancer (TNBC) | Phase 1 | Recruiting | Immunomic Therapeutics, Inc. | 60 | 2026-07-14 | 2026-09-10 |
| A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors SHY-ONC6 - Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC) | Phase 1 | Recruiting | SHY Therapeutics | 30 | 2026-06-24 | 2026-10-22 |
Showing 20 of 462. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (167) · Breast Neoplasms (153) · Ovarian Neoplasms (115) · Squamous Cell Carcinoma of Head and Neck (90) · Colorectal Neoplasms (78) · Melanoma (74) · Neoplasm Metastasis (74) · Carcinoma, Renal Cell (67) · Endometrial Neoplasms (66) · Stomach Neoplasms (65) · Neoplasms (61) · Uterine Cervical Neoplasms (58) · Pancreatic Neoplasms (48) · Small Cell Lung Carcinoma (48)
Skin Diseases (462) · Skin and Connective Tissue Diseases (462) · Neoplasms by Site (461) · Breast Diseases (460) · Neoplasms (401) · Breast Neoplasms (309) · Neoplasms by Histologic Type (205) · Respiratory Tract Neoplasms (196) · Thoracic Neoplasms (195) · Respiratory Tract Diseases (194) · Lung Diseases (193) · Urogenital Diseases (192) · Urogenital Neoplasms (190) · Female Urogenital Diseases (188) · Female Urogenital Diseases and Pregnancy Complications (188)
pembrolizumab (85) · Paclitaxel (34) · Carboplatin (33) · Cyclophosphamide (30) · Nivolumab (28) · 130-nm albumin-bound paclitaxel (17) · Cisplatin (15) · Gemcitabine (13) · Specimen Handling (13) · fludarabine (13) · Biopsy (12) · Capecitabine (12) · Magnetic Resonance Spectroscopy (12) · Taxes (12) · durvalumab (12)
National Cancer Institute (NCI) (29) · Novartis Pharmaceuticals (16) · AstraZeneca (10) · Pfizer (10) · AbbVie (8) · Eli Lilly and Company (8) · M.D. Anderson Cancer Center (8) · City of Hope Medical Center (5) · Mayo Clinic (5) · Washington University School of Medicine (5) · Bristol-Myers Squibb (4) · Exelixis (4) · Genmab (4) · Gilead Sciences (4) · H. Lee Moffitt Cancer Center and Research Institute (4)
United States (334) · Spain (78) · Australia (58) · France (55) · Canada (53) · United Kingdom (47) · China (44) · Italy (37) · Japan (36) · Belgium (34) · South Korea (29) · Germany (24) · Taiwan (23) · Israel (19) · Netherlands (19)
Soo Chin Lee (3) · David Page, MD (2) · Erika P Hamilton, MD (2)
PMID 32379297, PMID 22248721, PMID 23430121, PMID 23810467, PMID 24063698, PMID 25218906, PMID 25915780, PMID 25944802, PMID 25947565, PMID 26106073, PMID 26541586, PMID 26774555, PMID 27484900, PMID 27935867, PMID 28291390, PMID 28548889, PMID 28558150, PMID 28679770, PMID 29109077, PMID 29322091, PMID 29423221, PMID 29735994, PMID 30345906, PMID 30400780, PMID 30627694, PMID 30680712, PMID 30689707, PMID 30786188, PMID 30887250, PMID 31177991, PMID 31189049, PMID 31194225, PMID 31194228, PMID 31395751, PMID 31400383, PMID 31700871, PMID 31703728, PMID 31850192, PMID 32179633, PMID 32193378, PMID 32278621, PMID 32364844, PMID 32450725, PMID 32523090, PMID 32719455, PMID 32770720, PMID 32946924, PMID 32971187, PMID 33201358, PMID 33207944
2023 (15), 2016 (11), 2017 (11), 2014 (8), 2018 (8), 2019 (8), UM1CA186709 (8), 2025 (4), 2015 (3), P30CA016672 (3), P30CA068485 (3), UM1CA186712 (3), P30CA006516 (2), P30CA016058 (2), P30CA022453 (2)